About UsThe Company
Physiomics uses systems biology and develops cutting-edge mathematical models of cancer, supporting pharmaceutical decision making throughout the entire drug discovery process. We enable clients to increase efficiency and reduce development times, minimising the development risk and increasing their success rates.
Physiomics consults on specific pharmaceutical development projects and will also consider trouble-shooting problem cancer projects in exchange for product licenses or success fees and royalties for customers. Physiomics also works in collaboration with partners on technology developments such as virtual tumours.
Since 2007, Physiomics has been providing continued support to Lilly’s oncology program, studying cancer cellular processes for drugs targeting the cell cycle. It has also licensed customised versions of its ModelPlayer to Lilly, allowing them to perform their own simulations of anticancer agents using Physiomics’ models.
In 2010, Physiomics has entered into a collaboration with Sareum, in which Physiomics provides in silico simulations to support Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).
In 2004, Physiomics entered into a strategic alliance with Bayer Technology Services GmbH (BTS) to integrate PK-Sim® with its novel biological simulations.
ValiRx (previously known as Cronos Therapeutics Ltd) and Physiomics have also collaborated from 2004 to 2007 on the development of certain GeneICE (DNA silencing) therapeutics for cancer.
